| Stereochemistry | RACEMIC |
| Molecular Formula | C17H26N2O4S.ClH |
| Molecular Weight | 390.925 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1CCCC1CNC(=O)C2=CC(=CC=C2OC)S(=O)(=O)CC
InChI
InChIKey=IGOWMQPOGQYFFM-UHFFFAOYSA-N
InChI=1S/C17H26N2O4S.ClH/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3;/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20);1H
Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist. It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.
CNS Activity
Originator
Approval Year
Sample Use Guides
Oral Psychoses: Adult: Acute and chronic psychoses: 400-800 mg daily. May also be given via IM inj.
Oral Chronic aggression: Adult: 400-600 mg daily.
Intramuscular Psychoses: Adult: Up to 800 mg daily.
Route of Administration:
Oral
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
